ACE2 expression in adipose tissue is associated with cardio-metabolic risk factors and cell type composition-implications for COVID-19.
Journal
International journal of obesity (2005)
ISSN: 1476-5497
Titre abrégé: Int J Obes (Lond)
Pays: England
ID NLM: 101256108
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
received:
24
06
2021
accepted:
28
04
2022
revised:
21
04
2022
pubmed:
20
5
2022
medline:
28
7
2022
entrez:
19
5
2022
Statut:
ppublish
Résumé
COVID-19 severity varies widely. Although some demographic and cardio-metabolic factors, including age and obesity, are associated with increasing risk of severe illness, the underlying mechanism(s) are uncertain. In a meta-analysis of three independent studies of 1471 participants in total, we investigated phenotypic and genetic factors associated with subcutaneous adipose tissue expression of Angiotensin I Converting Enzyme 2 (ACE2), measured by RNA-Seq, which acts as a receptor for SARS-CoV-2 cellular entry. Lower adipose tissue ACE2 expression was associated with multiple adverse cardio-metabolic health indices, including type 2 diabetes (T2D) (P = 9.14 × 10 Our results demonstrate that individuals with cardio-metabolic features known to increase risk of severe COVID-19 have lower background ACE2 levels in this highly relevant tissue. Reduced adipose tissue ACE2 expression may contribute to the pathophysiology of cardio-metabolic diseases, as well as the associated increased risk of severe COVID-19.
Sections du résumé
BACKGROUND
COVID-19 severity varies widely. Although some demographic and cardio-metabolic factors, including age and obesity, are associated with increasing risk of severe illness, the underlying mechanism(s) are uncertain.
SUBJECTS/METHODS
In a meta-analysis of three independent studies of 1471 participants in total, we investigated phenotypic and genetic factors associated with subcutaneous adipose tissue expression of Angiotensin I Converting Enzyme 2 (ACE2), measured by RNA-Seq, which acts as a receptor for SARS-CoV-2 cellular entry.
RESULTS
Lower adipose tissue ACE2 expression was associated with multiple adverse cardio-metabolic health indices, including type 2 diabetes (T2D) (P = 9.14 × 10
CONCLUSIONS
Our results demonstrate that individuals with cardio-metabolic features known to increase risk of severe COVID-19 have lower background ACE2 levels in this highly relevant tissue. Reduced adipose tissue ACE2 expression may contribute to the pathophysiology of cardio-metabolic diseases, as well as the associated increased risk of severe COVID-19.
Identifiants
pubmed: 35589964
doi: 10.1038/s41366-022-01136-w
pii: 10.1038/s41366-022-01136-w
pmc: PMC9119844
mid: EMS144632
doi:
Substances chimiques
Angiotensin-Converting Enzyme 2
EC 3.4.17.23
Types de publication
Journal Article
Meta-Analysis
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1478-1486Subventions
Organisme : Medical Research Council
ID : MR/R023131/1
Pays : United Kingdom
Organisme : NIDDK NIH HHS
ID : U01 DK062370
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK020572
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK093757
Pays : United States
Organisme : Wellcome Trust
ID : 221574
Pays : United Kingdom
Organisme : NIDDK NIH HHS
ID : R01 DK062370
Pays : United States
Organisme : Medical Research Council
ID : MR/M004422/1
Pays : United Kingdom
Commentaires et corrections
Type : UpdateOf
Informations de copyright
© 2022. The Author(s).
Références
JAMA. 2020 Jun 16;323(23):2427-2429
pubmed: 32432657
Cell. 2020 May 28;181(5):1016-1035.e19
pubmed: 32413319
Genome Med. 2015 Aug 13;7:88
pubmed: 26391122
Nature. 2017 Oct 11;550(7675):204-213
pubmed: 29022597
Nat Rev Endocrinol. 2019 Sep;15(9):507-524
pubmed: 31296970
Obesity (Silver Spring). 2020 May;28(5):847
pubmed: 32237212
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
Am J Hum Genet. 2017 Mar 2;100(3):428-443
pubmed: 28257690
Nat Commun. 2017 May 18;8:15452
pubmed: 28516912
Nature. 2017 Oct 11;550(7675):244-248
pubmed: 29022598
PLoS Pathog. 2020 Sep 24;16(9):e1008817
pubmed: 32970782
Lancet. 2020 Feb 22;395(10224):565-574
pubmed: 32007145
Bioinformatics. 2012 Aug 15;28(16):2184-5
pubmed: 22743226
Nat Genet. 2012 Oct;44(10):1084-9
pubmed: 22941192
Nat Genet. 2015 Jan;47(1):88-91
pubmed: 25436857
Obesity (Silver Spring). 2020 Jul;28(7):1178-1179
pubmed: 32314871
Obesity (Silver Spring). 2020 Jul;28(7):1191-1194
pubmed: 32314868
Front Med (Lausanne). 2021 Apr 22;8:603374
pubmed: 33968947
Lancet. 2007 Apr 7;369(9568):1208-19
pubmed: 17416265
Obes Facts. 2020;13(4):439-452
pubmed: 32791497
Genome Biol. 2014;15(12):550
pubmed: 25516281
JAMA. 2020 Jun 16;323(23):2386-2387
pubmed: 32432681
Nat Microbiol. 2020 Dec;5(12):1598-1607
pubmed: 33106674
Nat Methods. 2015 May;12(5):453-7
pubmed: 25822800
Nature. 2002 Jun 20;417(6891):822-8
pubmed: 12075344
Am J Hum Genet. 2016 Sep 1;99(3):567-579
pubmed: 27588447
Int J Pept. 2012;2012:256294
pubmed: 22536270
JAMA Cardiol. 2020 Jul 1;5(7):747-748
pubmed: 32242886
Lancet Infect Dis. 2020 May;20(5):533-534
pubmed: 32087114
Thromb Res. 2020 Jul;191:9-14
pubmed: 32353746
Nature. 2005 Jul 7;436(7047):112-6
pubmed: 16001071
Proc Natl Acad Sci U S A. 2008 Jun 3;105(22):7809-14
pubmed: 18490652
Front Med (Lausanne). 2021 Jan 13;7:563893
pubmed: 33521006
Am J Hum Genet. 2012 Nov 2;91(5):839-48
pubmed: 23103226
Biochem Biophys Res Commun. 2010 May 21;396(1):101-4
pubmed: 20494119
Am J Hum Genet. 2019 Jun 6;104(6):1013-1024
pubmed: 31130283
Obes Rev. 2020 Sep;21(9):e13077
pubmed: 32567171
Nucleic Acids Res. 2019 Jan 8;47(D1):D766-D773
pubmed: 30357393
Nat Commun. 2016 Jun 29;7:11764
pubmed: 27353450
Thromb Res. 2020 Jul;191:145-147
pubmed: 32291094
Twin Res Hum Genet. 2013 Feb;16(1):144-9
pubmed: 23088889
Am J Hum Genet. 2019 Oct 3;105(4):773-787
pubmed: 31564431
Nat Med. 2005 Aug;11(8):875-9
pubmed: 16007097
ISRN Inflamm. 2013 Dec 22;2013:139239
pubmed: 24455420
Clin Chem Lab Med. 2020 Jun 25;58(7):1116-1120
pubmed: 32172226
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
J Clin Invest. 2003 Dec;112(12):1796-808
pubmed: 14679176
Nat Rev Cardiol. 2020 May;17(5):259-260
pubmed: 32139904
BMJ. 2020 May 22;369:m1985
pubmed: 32444460